SRNE - Sorrento Therapeutics' Next-Generation COVID-19 Therapeutic Antibody

In this video from Motley Fool Live recorded on Nov. 12, executives from Sorrento Therapeutics (NASDAQ: SRNE) talk about the company's second-generation therapeutic antibody. An investigational new drug (IND) application has been submitted to the Food and Drug Administration.

Mark Brunswick, senior vice president of regulatory affairs at Sorrento, talks about how much better STI-2020 (COVI-AMG) is than the first-generation version STI-1499 (COVI-GUARD). And Henry Ji, Sorrento's chairman, president, and CEO, highlights a third-generation version that uses DNA to express the antibody inside a patient's cells.

Continue reading

For further details see: